Michael Jon Brown Sells 1,700 Shares of DexCom (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Michael Jon Brown sold 1,700 shares of the firm’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $63.04, for a total value of $107,168.00. Following the completion of the sale, the executive vice president directly owned 111,204 shares of the company’s stock, valued at $7,010,300.16. This trade represents a 1.51% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Jon Brown also recently made the following trade(s):

• On Monday, March 16th, Michael Jon Brown sold 1,700 shares of DexCom stock. The shares were sold at an average price of $64.85, for a total value of $110,245.00.

DexCom Trading Up 4.5%

Shares of DexCom stock opened at $63.98 on Friday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.59 and a current ratio of 1.88. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $89.98. The stock has a 50 day moving average price of $67.36 and a two-hundred day moving average price of $66.73. The stock has a market capitalization of $24.69 billion, a PE ratio of 30.47, a price-to-earnings-growth ratio of 1.19 and a beta of 1.55.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.03. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The firm had revenue of $1.26 billion during the quarter, compared to analysts’ expectations of $1.25 billion. During the same quarter last year, the firm posted $0.45 earnings per share. The company’s revenue for the quarter was up 13.1% compared to the same quarter last year. As a group, equities analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analysts Set New Price Targets

DXCM has been the topic of a number of recent research reports. BTIG Research restated a “buy” rating and issued a $85.00 target price on shares of DexCom in a report on Monday, March 9th. Truist Financial restated a “buy” rating and issued a $80.00 target price (down from $82.00) on shares of DexCom in a report on Tuesday, February 17th. Robert W. Baird set a $87.00 target price on DexCom in a report on Friday, February 13th. Piper Sandler restated an “overweight” rating on shares of DexCom in a report on Thursday, February 5th. Finally, Mizuho raised their target price on DexCom from $78.00 to $90.00 and gave the company an “outperform” rating in a report on Friday, February 13th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and an average price target of $86.50.

Institutional Trading of DexCom

Hedge funds have recently bought and sold shares of the business. Gradient Investments LLC lifted its holdings in DexCom by 13.8% during the fourth quarter. Gradient Investments LLC now owns 332,006 shares of the medical device company’s stock worth $22,035,000 after acquiring an additional 40,343 shares during the period. E. Ohman J or Asset Management AB lifted its holdings in DexCom by 400.2% during the third quarter. E. Ohman J or Asset Management AB now owns 77,492 shares of the medical device company’s stock worth $5,214,000 after acquiring an additional 62,000 shares during the period. Zevenbergen Capital Investments LLC lifted its holdings in DexCom by 10.0% during the third quarter. Zevenbergen Capital Investments LLC now owns 685,433 shares of the medical device company’s stock worth $46,123,000 after acquiring an additional 62,098 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in DexCom by 11.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 212,045 shares of the medical device company’s stock worth $14,269,000 after acquiring an additional 21,352 shares during the period. Finally, Nordea Investment Management AB lifted its holdings in DexCom by 118.6% during the fourth quarter. Nordea Investment Management AB now owns 254,315 shares of the medical device company’s stock worth $16,988,000 after acquiring an additional 137,986 shares during the period. 97.75% of the stock is currently owned by institutional investors.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.